{{Rsnum
|rsid=456210
|Chromosome=20
|position=46453332
|Orientation=plus
|GMAF=0.3926
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 41.6 | 51.3 | 7.1
| HCB | 47.4 | 43.8 | 8.8
| JPT | 42.5 | 44.2 | 13.3
| YRI | 7.5 | 36.7 | 55.8
| ASW | 3.5 | 50.9 | 45.6
| CHB | 47.4 | 43.8 | 8.8
| CHD | 52.8 | 38.0 | 9.3
| GIH | 37.6 | 47.5 | 14.9
| LWK | 6.4 | 31.8 | 61.8
| MEX | 41.4 | 53.4 | 5.2
| MKK | 10.9 | 39.1 | 50.0
| TSI | 47.1 | 42.2 | 10.8
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs456210
|Name_s=
|Gene_s=ZNF663
|Feature=
|Evidence=PubMed ID:17537913
|Annotation=Risk or phenotype-associated allele: not stated Phenotype: Using a Quantitative Transmission Disequilibrium Test (QTDT), this variant was significantly associated with etoposide toxicity based upon IC50 values in cell lines from 30 parent-child trios. Study size: 176. Study population/ethnicity: 87 European descent Caucasians and 89 Yorubans. Significance metric(s): p = 0.00003. Type of association: FA; GN.
|Drugs=etoposide
|Drug Classes=
|Diseases=Drug Toxicity
|Curation Level=Curated
|PharmGKB Accession ID=PA165109526
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs456210
|overall_frequency_n=64
|overall_frequency_d=128
|overall_frequency=0.5
|n_genomes=39
|n_genomes_annotated=0
|n_haplomes=57
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}